COVID-19 vaccine: BioNTech, Pfizer begin German part of study
Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement PFIZER LTD. - 500680 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Pfizer Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here PFIZER LTD. - 500680 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the scrutinizer's report on the remote e-voting and e-voting during the 69th Annual General Meeting of the Company held on September 4, 2020. We request you to kindly take the same on record. PFIZER LTD. - 500680 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed proceedings of the 69th Annual General Meeting of the Company held on September 4, 2020 at 3.00 p.m. and concluded at 5.28 p.m. We request you to kindly take the same on record. COVID-19 vaccine: Canada inks deals with Novavax, Johnson & Johnson for millions of doses
Canada's two agreements follow separate deals with Pfizer Inc and Moderna Inc announced weeks ago, and are the latest example of countries rushing to secure access to vaccines COVID-19 vaccine: Novavax begins enrolment for phase 2 trials
The vaccine candidate is one of nearly 30 being tested in human clinical trials globally and lags candidates from AstraZeneca, Pfizer and Moderna that are in late-stage studies
Pfizer, BioNTech shares gain as more data backs vaccine candidate
Pfizer shares rose 1% while those of BioNTech were 6% higher before the bell Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates and issue of duplicate share certificates. Covid-19 vaccine by US pharma giant Pfizer shows promising results in early trials
The early trials of the Covid-19 vaccine that is being developed by the pharmaceutical giant Pfizer have shown promising and safe results.The results